PolyPid Ltd.

PYPD

IL0011326795

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.5 USD

Average target price

12.33 USD

Spread / Average Target

+174.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
POLYPID LTD.	+17.11%	21.59M
ELI LILLY AND COMPANY	+28.10%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.84%	356B
MERCK & CO., INC.	+14.71%	320B
ABBVIE INC.	+4.88%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.77%	142B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-16 pm EDT			5-day change	1st Jan Change
4.45 ^USD	-1.11%		+4.71%	+17.11%

Feb. 14	Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
Feb. 14	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial	Feb. 12	CI
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.	Jan. 21	CI
PolyPid Enters Into $16.2 Million Private Placement Deal	Jan. 05	MT
PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors	Jan. 03	CI
Transcript : PolyPid Ltd., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors	Nov. 07	CI
HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16	23-10-12	MT
Polypid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-Plex100 and Plex Technology Platform	23-10-04	CI
Top Premarket Decliners	23-09-27	MT
Top Premarket Decliners	23-09-26	MT
PolyPid Facility for D-PLEX100 Has no Critical Findings From Israeli Health Ministry Audit	23-09-21	MT
PolyPid to Implement 1-for-30 Reverse Stock Split	23-09-20	MT
PolyPid Completes Manufacturing-Process Validation for D-PLEX	23-09-19	DJ
PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100	23-09-19	CI
Transcript : PolyPid Ltd., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
PolyPid Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections	23-06-29	CI
Certain Warrants of PolyPid Ltd. are subject to a Lock-Up Agreement Ending on 28-JUN-2023.	23-06-27	CI
Certain Options of PolyPid Ltd. are subject to a Lock-Up Agreement Ending on 28-JUN-2023.	23-06-27	CI
Certain Ordinary Shares of PolyPid Ltd. are subject to a Lock-Up Agreement Ending on 28-JUN-2023.	23-06-27	CI
PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections	23-06-22	CI
FDA Approves PolyPid's Trial Design for D-PLEX	23-05-22	DJ

PolyPid Ltd.

Equities